Rein Therapeutics (RNTX) Common Equity (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Common Equity of $11.6 million for Q1 2026, down 76.76% year-over-year from $49.9 million in Q1 2025, and down 31.49% quarter-over-quarter from $16.9 million in Q4 2025.
Rein Therapeutics (RNTX) Common Equity (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Common Equity for 11 consecutive years, with $11.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 76.76% year-over-year to $11.6 million; the TTM figure through Mar 2026 stood at $11.6 million (down 76.76% YoY), while the FY2025 annual figure was $16.9 million, down 68.9% from the prior year.
- Common Equity retreated to $11.6 million in Q1 2026 per RNTX's latest filing, from $16.9 million in the prior quarter.
- Across five years, Common Equity topped out at $101.0 million in Q2 2024 and bottomed at $11.2 million in Q3 2023.
- Historically, Common Equity has averaged $44.5 million across 5 years, with a median of $36.1 million in 2022.
- Annual changes were most pronounced in 2024 — Common Equity jumped 750.44% — and 2026, when it plunged 76.76%.
- Rein Therapeutics' Common Equity stood at $18.6 million in 2022, then soared by 427.83% to $98.3 million in 2023, then sank by 44.67% to $54.4 million in 2024, then sank by 68.9% to $16.9 million in 2025, then tumbled by 31.49% to $11.6 million in 2026.
- Business Quant data shows RNTX's Common Equity at $11.6 million in Q1 2026, $16.9 million in Q4 2025, and $46.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 9.79 Bn |
| 10 | Rein Therapeutics | 55.87 Mn | 55.87 Mn | - | 55.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.20 Mn |
| Mar 31, 2026 | 11.59 Mn |
| Dec 31, 2025 | 16.92 Mn |
| Sep 30, 2025 | 46.19 Mn |
| Jun 30, 2025 | 48.01 Mn |
| Mar 31, 2025 | 49.88 Mn |
| Dec 31, 2024 | 54.39 Mn |
| Sep 30, 2024 | 95.23 Mn |
| Jun 30, 2024 | 101.02 Mn |
| Mar 31, 2024 | 91.33 Mn |
| Dec 31, 2023 | 98.30 Mn |
| Sep 30, 2023 | 11.20 Mn |
| Jun 30, 2023 | 12.79 Mn |
| Mar 31, 2023 | 14.27 Mn |
| Dec 31, 2022 | 18.62 Mn |
| Sep 30, 2022 | 22.70 Mn |
| Jun 30, 2022 | 28.62 Mn |
| Mar 31, 2022 | 36.11 Mn |
| Dec 31, 2021 | 43.90 Mn |
| Sep 30, 2021 | 50.11 Mn |